Mucormycosis of the Spine: A Case Report and Review of the Literature

Jaimin Patel 1, Zach Pennington 2, Andrew M. Hersh 1, Bethany Hung 1, Daniel M. Scuibba 3, Sheng-Fu L. Lo 3

Abstract

Mucormycosis is an extremely rare, invasive infection commonly isolated to patients with known immunosuppressed status. In the present case, a 36-year-old woman, with a history of T-cell acute lymphoblastic leukemia in remission, presented with T4 osteomyelitis and an associated epidural collection. Biopsy was consistent with mucormycosis, and the patient was recommended for surgical debridement. After declining debridement, the patient was successfully managed on a multiagent antifungal regimen consisting of intravenous amphotericin B, micafungin, and oral posaconazole. The patient was alive without clear evidence of disease at eight months, representing one of the first cases of spinal mucormycosis infection successfully treated with medical management alone. We additionally review the previous descriptions of spinal mucormycosis infections to identify those interventions most associated with successful clearance or containment of these infections.

Keywords: t-cell all, antifungal, epidural abscess, osteomyelitis, spinal mucormycosis

Introduction

Spinal epidural abscesses are an increasingly common clinical pathology, with reports suggesting their presence in approximately one in every 100,000 patients [1] and one in every 10-20,000 hospital admissions in the United States [2,3]. However, the prevalence of this condition can vary based on geographical location. Medical and surgical management paradigms have been described [4,5], with the preferred treatment often depending upon the implicated microbial species. Most infections appear to occur secondary to Streptococcus and Staphylococcus aureus species, including methicillin-resistant S. aureus (MRSA) [4]. However, fungal [6] and mycobacterial infections [7] have been reported. Fungal infections (e.g., Candida and Aspergillus) have been reported to account for <1% of all cases, and they disproportionately affect immunocompromised patients [6]. Rarer still are infections from Rhizopus species (mucormycosis), of which there are only a handful of cases [8-19]. Here, we report a case of spinal mucormycosis in an immunocompromised patient with long-term survival, along with a proposed management algorithm based upon the reported literature.

Case Presentation

A 36-year-old female with a history of T-cell acute lymphoblastic leukemia (T-ALL) presented to the emergency department for management of bilateral lower extremity paralysis and urinary/fecal incontinence. The patient had previously undergone treatment with first-line therapy (prednisone, daunorubicin, vincristine) and second-line therapy (nelarabine and concomitant radiation) for her T-ALL. She was undergoing treatment with intrathecal methotrexate and maintenance methotrexate-vincristine combination therapy when she developed acute onset bilateral lower extremity weakness. Imaging had demonstrated an epidural abscess. A T2-3 laminectomy and epidural fluid drainage were performed at an outside facility, after which she had developed flaccid paralysis of the bilateral lower extremities. Biopsy at this time showed no tumor cells. Of note, her treatment had been previously complicated by a zygomycetes fungal pneumonia nine months prior to presentation, which had been successfully treated with isavuconazole. However, fungal cultures from the epidural fluid were not obtained. Due to her immunosuppressed status, she was on antimicrobial prophylaxis with sulfamethoxazole-trimethoprim, isavuconazole, and acyclovir at the time of admission.

On examination, the patient was 0/5 in the bilateral lower extremities, with absent rectal tone and a T6 sensory level. Magnetic resonance imaging (MRI) of the thoracic spine was obtained, which demonstrated collapse of the T4 vertebral body with an enhancing epidural mass circumferentially enveloping the cord and creating a T2-signal cord hyperintensity from the level of T2 to T6 (Figures 1A-1B). The patient was afebrile. Laboratory data demonstrated a leukocyte count of 4.45×10³/mL and a C-reactive protein level of 1.0 mg/dL. β-D-glucan, galactomannan, cryptococal, and Histoplasma antigen studies were negative. Her urinalysis was found to be positive for extended-spectrum β-lactamase producing Escherichia coli, indicating a potential urinary tract infection of unknown clinical significance.
FIGURE 1: MRI and CT images of the thoracic spine of the patient

(A) Sagittal slice from a T2-weighted MRI shows an ill-defined osteodestructive process of the T4 vertebra with anterior wedging (arrow) and enlargement of the posterior T3-5 cord (arrowheads). Also visible on the sagittal slice is the patient’s prior T2-3 laminectomy defect. (B) The axial slice illustrates that the pathology extended from the T4 body into the ventral and left ventrolateral space. There was also a transforaminal excursion into the left pleural space. The presence of a cerebrospinal fluid signal at the T4 level suggested the intrinsic cord T2 signal hyperintensity was likely secondary to ventral compression over the focal T4 kyphosis. (C, D) Sagittal pre- and post-contrast-enhanced T1-weighted FLAIR sequences show heterogeneous enhancement of the mass. (E) A parasagittal non-contrast CT image shows near complete destruction of the T4 vertebra.

Because of her known epidural collection lacking microbial characterization and the unrevealing hematology, a biopsy of the epidural collection was performed, which demonstrated heavy hyphal elements on calcofluor white stain, consistent with mucormycosis of the epidural space. Surgical debridement of the bone and drainage of the epidural abscess was recommended; however, the patient declined and opted for medical management. A Hickman catheter was placed, and she was discharged on a multagent regimen of intravenous amphotericin B (7.5mg/kg daily), intravenous micafungin (100mg daily), and oral posaconazole (300mg daily). After 12 weeks, she was transitioned to monotherapy with oral posaconazole. She remains alive on maintenance posaconazole at eight months follow-up with flaccid paralysis.

Discussion

Mucormycosis (zygomycosis) is a fungal infection caused by mucormycetes (zygomycetes) molds, most commonly manifesting as cavitary lung lesions or rhinocerebral infection in immunocompromised individuals (e.g., those on immunosuppressive medications) or patients with poorly controlled diabetes mellitus [20]. Microscopy is the gold standard of diagnosis and demonstrates large, nonseptate hyphae branching at right angles with angioinvasion, local tissue necrosis, and neutrophilic inflammation [20,21]. It is capable of spreading rapidly along nerves and blood vessels, leading to invasive mucormycosis, which is known to have a dismal prognosis. Few descriptions of spinal mucormycosis infections exist, and the present case represents only the 11th case in the medical literature (Table 1) [8-19]. This limited literature has precluded the development of optimal management strategies, and to date, there have been no definitive guidelines for managing spinal mucormycosis.

| Case         | Patient Details                                                                 | Species | Location | Immuno-suppressed? | Tx                           | Outcome          |
|--------------|---------------------------------------------------------------------------------|---------|----------|--------------------|------------------------------|------------------|
| Buruma et al, 1979 [19] | 60yo M w/ hx head and neck surgery/ R cervical LN dissection for carcinoma and hx neck XRT + L neck XRT ulcer + tracheostomy Neuro Sx: cervical myelopathy | n.g.    | C3-4 OM C1-5 SEA | Y                  | None                         | Deceased 1d s/p admission |
| Rozich 1988 [18] | 52yo M w/ hx splenectomy and MDS s/p chemo Neuro Sx: presented with cauda equina syndrome | n.g.    | L2-4 SEA | Y                  | Surg: -L3-5 lami; L4/5 disectomy -fu L1-2 lami Med: IV AmpB x12d | Deceased 16d s/p admission |
### TABLE 1: Literature review of previously published cases of mucormycosis with dissemination to the spine

| Author(s) | Year | Age | Gender | Diagnosis | Symptoms | Treatment | Outcome |
|-----------|------|-----|--------|-----------|----------|-----------|---------|
| von Pohle 1996 | [15] | 43yo M w/ DM in diabetic ketoacidosis Neuro Sys: b/l leg weakness → quadriplegia | n.g. | T3-4 OM; T3-8 meningitis | Y | Med: AmpB @ 1 mg/kg/d ×2d | Deceased 2d s/p admission |
| Chen et al. 2006 | [9] | 57yo F w/ recent hx of L4/S radiofrequency nucleoplasty NeuroSys: back pain + b/l leg weakness + numbness | R. rhizopodiformis | L4-5 OM + SEA | N | Surg: L5-4 laminectomy; T3-8 meningitis | Alive w/ disease (small SEA) @ 1yr flu |
| Skiada et al. 2009 | [14] | 2yo M w/ AML on chemo Neuro Sys: status epilepticus + quadriplegia | A. corymbifera | TL junction SEA + intracerebral abscess | Y | Med: Empiric Tx: AmpB @ 5mg/kg/d Post-Cx: PO Vori + PO casp + IVnt AmpB @ 1mo + PO posaconazole @ 8wk + PO fluC @ 5 g/d + itra @ 200 mg BID + 12mo | Alive w/ disease @ 1yr fu |
| Tintelnot and Nitsche 2017 | [17] | 49yo M w/ C6 fracture/sublux 1wk s/p fusion Neuro Sys: None → neck pain + signs of surgical wound infection | R. oligosporus | C/T junction wound infection | N | Med: ampB @ 0.1→ 1mg/kg/d IV ×18d + local H₂O₂ + local povidone-iodine solution + local ampB instillation ×4d | Alive @ 6mo fu |
| Giuliani et al. 2010 | [13] | 54yo F w/ DM and cutaneous lesion Neuro Sys: T12 sensory level w/ b/l leg paraparesis/paraplegia; long tract signs | R. arrhizus | T10-12 cord lesion | Y | Surg: QD debridement + curettage × 7mo Med: Post Cx: IV ampB @ 300 mg/d ×3mo | Alive at 2yr flu; unclear disease status |
| Navanukroh et al. 2014 | [12] | 42yo F w/ CKD 4d s/p kidney transplant on multiagent immunosuppression Neuro Sys: L leg sciatica | C. bertholletiae | L4-S1 SEA + S1 OM | Y | Surg: L-S1 lami; 5mL abscess evacuation Med: Empiric Tx: IV ampB @ 40 mg/d Post-Cx: IV ampB @ 200 mg/d ×3mo + PO posaconazole @ 800 mg/d ×1wk | Alive w/ disease @ LFU |
| Hadgaonkar et al. 2015 | [10] | 64yo M w/ hx DM, HTN, CKD Neuro Sys: low back pain; neuro intact | n.g. | L4-5 OM + L4/5 diskitis | Y | Med: IV ampB | Deceased 3wk s/p admission |
| Shah and Nene, 2017 | [8] | 54yo M w/ cirrhosis, portal HTN, pancytopenia Neuro Sys: mechanical low back pain + R leg sciatica | n.g. | L3-4 OM | Y | Med: AmpB @ 5mg/kg/d | Deceased 2wk s/p admission |
| Present Case | | 36yo F w/ hx/ chemo T-ALL s/p chemo Sys: chronic b/l leg paresis, T6 sensory level | n.g. | T4 OM, T2-6 SEA | Y | Medical: Ppx: PO Isov 372mg/d Tx IV ampB-7.5 mg/kg/d×12 wk, IV micafungin-100 mg/d ×12wk, + PO Posaconazole @ 300mg/d ×12wk Maintenance PO posa @ 300mg/d ×8mo | Alive at 8mo fu; persistent epidural collection at 4mo flu; no histologic evidence of disease |

**Key:**
- **AML:** acute myeloid leukemia
- **ampB:** amphotericin B
- **BID:** twice daily
- **casp:** caspofungin
- **CKD:** chronic kidney disease
- **dx:** culture
- **DM:** diabetes mellitus
- **F:** female
- **flu:** fluconazole
- **flucytosine:** flu → follow-up
- **HTN:** hypertension
- **IC:** immunocompromised
- **isov:** isovuconazole
- **itra:** itraconazole
- **IVnt:** intraventricular
- **kg:** kilogram
- **L:** left
- **LNM:** lymph node
- **MDS:** myelodysplastic syndrome
- **mg:** milligram
- **mo:** month
- **n.g.:** not given
- **OM:** osteomyelitis
- **PO:** oral
- **posa:** posaconazole
- **pxx:** prophylaxis
- **R:** right
- **SEA:** spinal epidural abscess
- **s/p:** status-post (after)
- **Sx:** symptoms
- **T-ALL:** T-cell acute lymphoblastic leukemia
- **Tx:** treatment
- **vori:** voriconazole
- **wk:** week
- **XRT:** radiotherapy

The first description of spinal mucormycosis was by Buruma et al., who reported an occurrence in a 60-year-old man with a prior history of previously resected oropharyngeal cancer and prior neck irradiation with a
persistent radiation-induced neck ulcer [19]. The patient presented with signs of cervical myelopathy, and preliminary imaging showed posterior vertebral body erosions at multiple levels, suspicious for metastatic disease. He rapidly declined, and only on post-mortem were mucor species detected.

In all other reported cases, mucormycosis was diagnosed in time to guide management. However, from these cases, it is apparent that outcomes are extremely poor in immunocompromised patients. Of the eight cases in immunocompromised patients (including the present case), overall mortality has been 30%. Rapid declines were reported in all cases, with von Pöhle reporting death two days after admission [15], Rozich reporting death 16 days post-admission [18], Hadgaonkar three weeks post-admission [10], and Shah and Nene documenting death two weeks post-admission [8]. In the three cases besides the present case who were alive at last follow-up, one had persistent epidural disease [12], and another was in a persistent vegetative state secondary to a concurrent intracerebral mucor infection [14]. The only immunocompromised patient to have achieved clearance was a 54-year-old woman treated by Giuliani et al. [13], who had undergone daily debridements and intravenous amphotericin B treatments over months. Unfortunately, she had suffered a T10-12 cord infarction secondary to her angiioinvasive mucor disease and was left permanently paraparetic. Nevertheless, this demonstrates the uniqueness of the successful medical management that was achieved in the present patient.

Outcomes for immunocompetent patients have been dramatically better and, as with the Buruma et al. case [19], all patients had a predisposing risk factor for inoculation into the spine. In the first case, the patient had a chronic radiation-induced neck ulcer with underlying carotid artery exposure. This facilitated direct access of cutaneous microbes to the deep tissues of the neck. Similarly, in the case reported by Tintelnot and Nitsche [17], the patient had undergone an open reduction of a C6 fracture-subluxation one week prior to presentation. Likewise, in the case of Chen and colleagues [9], the patient had undergone an L4/S radiofrequency nucleoplasty shortly before documentation of a mucormycosis infection of the L4 and L5 bodies with ventral epidural expansion.

In all cases, definitive treatment has hinged upon aggressive intravenous antifungal management with amphotericin B. Doses have ranged from 20mg per day to 10mg per kg bodyweight per day, with prolonged courses of 8-12 weeks for patients with long-term reported follow-up. Additionally, in the six patients who have survived at least six months following diagnosis of the infection, rapid surgical debridement was pursued in three [9,12,13]. Those cases in which surgical debridement was not pursued fell into two categories. The first was patients considered to be poor surgical candidates - the present case and that of Skienda et al. [14] - though in our case, surgical debridement was still recommended based upon the poor prognosis without debridement. The second group - the case of Tintelnot and Nitsche [17] - was in an immunocompetent adult without evidence of penetration into the vertebral bodies or epidural space. Consequently, evidence at present appears to favor aggressive surgical debridement. In those patients who cannot tolerate surgical debridement, aggressive antifungal regimens are warranted, and the prognosis is likely extremely morbid.

Successful treatment regimens appear to have also included either dual-agent antifungal therapy or local/topical antifungals in addition to intravenous therapy. Four cases, including the present, combined amphotericin with anti-mucormycetes azoles (e.g., voriconazole, isovaconazole, itraconazole) or echinocandins (e.g., caspofungin, micafungin) [9,12,14]. In two cases, surgical wounds were irrigated daily with colloidal amphotericin B preparations [9,17]. The latter serves to both increase amphotericin concentrations in the infection site, and to allow for the use of lower systemic amphotericin concentrations, as amphotericin is known to be nephrotoxic [9]. This strategy of combined local and intravenous amphotericin B treatment has been described for other invasive mucor infections and may represent an ideal strategy for achieving effective fungicidal levels while minimizing the risk of nephrotoxic injury [22,23]. Lastly, only in the case of Tintelnot and Nitsche was radiographic evidence of disease clearance achieved [17]. This highlights the importance of a long-term antifungal maintenance regimen after completion of the intravenous amphotericin course and remission of all signs of acute infection. Such prophylaxis is especially important in immunocompromised patients and in the present case, oral posaconazole was employed.

Conclusions

The present case describes the medical management of an invasive mucormycosis infection of the spine in an immunosuppressed patient with a history of T-cell acute lymphoblastic leukemia. Prognosis in such infections is usually poor; however, in those cases that have been documented, successful treatment usually hinges upon aggressive surgical debridement and high-dose intravenous amphotericin B. The addition of local wound irrigation with amphotericin B solutions or dual-agent antifungal regimens including echinocandins or azole antifungals may also help to improve the patient’s likelihood of a good outcome.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Johns Hopkins Medicine Institutional Review Boards issued approval N/A. IRB approval was not required for the present study per
institutional guidelines. **Conflicts of interest:** In compliance with the ICJME uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** Daniel M Sciubba declare(s) personal fees from Augmedics. Daniel M Sciubba declare(s) personal fees from Baxter. Daniel M Sciubba declare(s) personal fees from DePuy-Synthes. Daniel M Sciubba declare(s) personal fees from Globus Medical. Daniel M Sciubba declare(s) personal fees from K2M. Daniel M Sciubba declare(s) personal fees from Medtronic. Daniel M Sciubba declare(s) personal fees from NuVasive. Daniel M Sciubba declare(s) personal fees from Stryker. Daniel M Sciubba declare(s) a grant from Baxter Medical. Unrelated grant support. Daniel M Sciubba declare(s) a grant from North American Spine Society. Unrelated grant support. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**Acknowledgements**

Jaimin Patel and Zach Pennington contributed equally to this work and should be considered co-first authors.

**References**

1. Makito K, Mouri H, Matsu H, Michihata N, Fushimi K, Yasunaga H: Spinal epidural hematoma and abscess after neuraxial anesthesia: a historical cohort study using the Japanese Diagnosis Procedure Combination database. Can J Anaeth. 2021, 68:42-52. 10.1007/s12630-020-01827-w
2. Vakili M, Crum-Cliffon NF: Spinal epidural abscess: a series of 101 cases. Am J Med. 2017, 130:1458-63. 10.1016/j.amjmed.2017.07.017
3. Schwab JH, Shah AA: Spinal epidural abscess: diagnosis, management, and outcomes. J Am Acad Orthop Surg. 2020, 28:e929-38. 10.5455/AAOS-D-19-00685
4. Longo M, Pennington Z, Gelfand Y, et al.: Readmission after spinal epidural abscess management in urban populations: a bi-institutional study. J Neurosurgery. Spine. 2020, 32:465-72. 10.3171/2019.8.SPINE19780
5. Wang TY, Harvard SC 2nd, Tsvankin Y, et al.: Neurological outcomes after surgical or conservative management of spontaneous spinal epidural abscesses: a systematic review and meta-analysis of data from 1980 through 2016. Clin Spine Surg. 2019, 32:18-29. 10.1097/BSD.0000000000001762
6. Yang H, Shah AA, Nelson SB, Schwab JH: Fungal spinal epidural abscess: a case series of nine patients. Spine J. 2019, 19:516-22. 10.1016/j.spinee.2018.08.001
7. Dai G, Li S, Yin C, et al.: Studies on 11 cases of spinal epidural abscess and literature review. Infect Drug Resist. 2020, 13:5325-54. 10.2147/IDR.S257398
8. Shah K, Nene A: Spinal mucormycosis. J Glob Infect Dis. 2017, 9:160-1. 10.4103/jgid.jgid_107_16
9. Chen F, Li G, Kang Y, et al.: Mucormycosis spondylodiscitis after lumbar disc puncture. Eur Spine J. 2006, 15:570-6. 10.1007/s00586-005-1025-0
10. Hadgaoantra S, Shah K, Bhujraj S, Nene A, Snyam A: Isolated mucormycotic spondylodiscitis of lumbar spine-a rare case report. J Orthop Case Rep. 2015, 5:55-7. 10.13107/jocr.2250-0685.275
11. De Pasquale A, Deprez M, Giaye B, et al.: Invasive pulmonary mucormycosis with invasion of the thoracic spine in a patient with myelodysplastic syndrome (Article in French). Revue Medicale de Liege. 2008, 63:702-6.
12. Navanukroh O, Jitmuang A, Chayakulkeeree M, Ngamskulrungroj P: Disseminated Cunninghamamella berthelotiiiae infection with spinal epidural abscess in a kidney transplant patient: case report and literature review. Transpl Infect Dis. 2014, 16:638-65. 10.1111/tid.12251
13. Giuliani A, Mettemano M, Viviani D, et al.: An uncommon case of systemic Mucormycosis associated with spinal cord infarction in a recently diagnosed diabetic. Int J Immunopathol Pharmacol. 2010, 23:355-8. 10.1177/039463201002500135
14. Skida A, Vrana L, Polychronopoulou H, Prodromou P, Chantzis A, Tofas P, Daikos GL: Disseminated zygomycosis with involvement of the central nervous system. Clin Microbiol Infect. 2009, 15 Suppl 6:546-9. 10.1111/j.1469-0691.2009.02980.x
15. von Fohle WR: Disseminated mucormycosis presenting with lower extremity weakness. Eur Respir J. 1996, 9:1751-3. 10.1183/09031996.96.09081751
16. Suzuki G, Kurousawa M, Takahashi Y, et al.: Transverse lesion of the spinal cord due to mucormycosis in an AML patient (Article in Japanese). Rinsho Ketsueki. 1996, 37:694-700.
17. TintiNLvN K, Nitsche B: Rhizopus oligosporus as a cause of mucormycosis in man. Mycoses. 1989, 32:115-8. 10.1111/j.1365-3114.1989.tb02216.x
18. Rozich J: Cauda equina syndrome secondary to disseminated zygomycosis. J Am Med Assoc. 1988, 260:3638-40. 10.1001/jama.1988.035014020410041
19. Buruma OJS, Craane H, Kunst MW: Vertebral osteomyelitis and epidural abscess due to mucormycosis. Clin Neurol Neurosurgery. 1979, 81:39-44. 10.1016/S0303-8467(79)80005-0
20. Spellberg B, Edwards J Jr, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005, 18:556-69. 10.1128/CMR.18.5.556-569.2005
21. Challa S: Mucormycosis: pathogenesis and pathology. Current Fung Inf Rep. 2019, 13:11-20. 10.1007/s12281-019-00357-1
database. Can J Anaeth. 2021, 68:42-52. 10.1007/s12630-020-01827-w
22. Steve AK, Hurdle VA, Brown JY: Orbitalisaxillofacial mucormycosis requiring complex multifactorial management. Plast Reconstr Surg Glob Open. 2018, 6:e1927. 10.1097/GOX.0000000000001927
23. Anderson A, McManus D, Perreault S, Lo YC, Seropian S, Topal JE: Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal mucorales in an immunocompromised patient. Med Mycol Case Rep. 2017, 17:11-15. 10.1016/j.mmcr.2017.05.004